Cargando…

Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic

INTRODUCTION: Opioid use disorder (OUD) is a debilitating illness that remains a serious public health issue in the United States. Use of telemedicine to deliver medications for the treatment of OUD (MOUD) was limited until the confluence of the COVID-19 and opioid addiction epidemics in spring 2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattocks, Kristin M., Moore, David T., Wischik, Dora Lendvai, Lazar, Christina M., Rosen, Marc I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949846/
https://www.ncbi.nlm.nih.gov/pubmed/35346533
http://dx.doi.org/10.1016/j.jsat.2022.108777
_version_ 1784675001075499008
author Mattocks, Kristin M.
Moore, David T.
Wischik, Dora Lendvai
Lazar, Christina M.
Rosen, Marc I.
author_facet Mattocks, Kristin M.
Moore, David T.
Wischik, Dora Lendvai
Lazar, Christina M.
Rosen, Marc I.
author_sort Mattocks, Kristin M.
collection PubMed
description INTRODUCTION: Opioid use disorder (OUD) is a debilitating illness that remains a serious public health issue in the United States. Use of telemedicine to deliver medications for the treatment of OUD (MOUD) was limited until the confluence of the COVID-19 and opioid addiction epidemics in spring 2020. Starting in spring 2020, the Department of Veterans Health Affairs (VHA) transitioned from in-person to mostly telemedicine-delivered OUD care to reduce COVID-19 transmission among veterans and providers. To gain a nuanced understanding of provider perspectives on MOUD care delivery using telemedicine, we conducted semi-structured interviews with VHA providers who were using telehealth to deliver MOUD care. METHODS: We conducted semi-structed Zoom interviews with VA clinicians at nine VA Medical Centers (VAMCs) in eight states. Potential study participants were identified as providers who were involved in referrals and provision of buprenorphine treatment for chronic pain and opioid addiction. Audio-recordings of all interviews were transcribed and entered into Atlas. Ti qualitative analysis software. The study team analyzed the transcripts for major themes related to tele-prescribing practices for buprenorphine. RESULTS: Twenty-three VA providers participated in the study, representing 32% of all providers invited to participate in the study. The research team identified the following four themes: (1) COVID-19 spurred a seismic shift in OUD treatment; (2) Video calls provided a rare window into veterans' lives; (3) Providers experienced numerous challenges to virtual visits; and (4) Providers wrestled with paternalism and trust. CONCLUSIONS: The pandemic accelerated the movement toward harm reduction approaches. Prior to the pandemic, stringent requirements existed for patients receiving MOUD care. Providers in this study reflected on the need for these requirements (e.g., in-person visits, toxicology screens) and how reducing this monitoring implied more trust in patients' autonomous decisions. Providers' observation that videoconferencing offered them a window into patients' lives may offer some ways to improve rapport, and research should explore how best to incorporate the additional information conveyed in virtual visits.
format Online
Article
Text
id pubmed-8949846
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Pergamon Press
record_format MEDLINE/PubMed
spelling pubmed-89498462022-03-25 Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic Mattocks, Kristin M. Moore, David T. Wischik, Dora Lendvai Lazar, Christina M. Rosen, Marc I. J Subst Abuse Treat Article INTRODUCTION: Opioid use disorder (OUD) is a debilitating illness that remains a serious public health issue in the United States. Use of telemedicine to deliver medications for the treatment of OUD (MOUD) was limited until the confluence of the COVID-19 and opioid addiction epidemics in spring 2020. Starting in spring 2020, the Department of Veterans Health Affairs (VHA) transitioned from in-person to mostly telemedicine-delivered OUD care to reduce COVID-19 transmission among veterans and providers. To gain a nuanced understanding of provider perspectives on MOUD care delivery using telemedicine, we conducted semi-structured interviews with VHA providers who were using telehealth to deliver MOUD care. METHODS: We conducted semi-structed Zoom interviews with VA clinicians at nine VA Medical Centers (VAMCs) in eight states. Potential study participants were identified as providers who were involved in referrals and provision of buprenorphine treatment for chronic pain and opioid addiction. Audio-recordings of all interviews were transcribed and entered into Atlas. Ti qualitative analysis software. The study team analyzed the transcripts for major themes related to tele-prescribing practices for buprenorphine. RESULTS: Twenty-three VA providers participated in the study, representing 32% of all providers invited to participate in the study. The research team identified the following four themes: (1) COVID-19 spurred a seismic shift in OUD treatment; (2) Video calls provided a rare window into veterans' lives; (3) Providers experienced numerous challenges to virtual visits; and (4) Providers wrestled with paternalism and trust. CONCLUSIONS: The pandemic accelerated the movement toward harm reduction approaches. Prior to the pandemic, stringent requirements existed for patients receiving MOUD care. Providers in this study reflected on the need for these requirements (e.g., in-person visits, toxicology screens) and how reducing this monitoring implied more trust in patients' autonomous decisions. Providers' observation that videoconferencing offered them a window into patients' lives may offer some ways to improve rapport, and research should explore how best to incorporate the additional information conveyed in virtual visits. Pergamon Press 2022-08 2022-03-25 /pmc/articles/PMC8949846/ /pubmed/35346533 http://dx.doi.org/10.1016/j.jsat.2022.108777 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mattocks, Kristin M.
Moore, David T.
Wischik, Dora Lendvai
Lazar, Christina M.
Rosen, Marc I.
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
title Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
title_full Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
title_fullStr Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
title_full_unstemmed Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
title_short Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
title_sort understanding opportunities and challenges with telemedicine-delivered buprenorphine during the covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949846/
https://www.ncbi.nlm.nih.gov/pubmed/35346533
http://dx.doi.org/10.1016/j.jsat.2022.108777
work_keys_str_mv AT mattockskristinm understandingopportunitiesandchallengeswithtelemedicinedeliveredbuprenorphineduringthecovid19pandemic
AT mooredavidt understandingopportunitiesandchallengeswithtelemedicinedeliveredbuprenorphineduringthecovid19pandemic
AT wischikdoralendvai understandingopportunitiesandchallengeswithtelemedicinedeliveredbuprenorphineduringthecovid19pandemic
AT lazarchristinam understandingopportunitiesandchallengeswithtelemedicinedeliveredbuprenorphineduringthecovid19pandemic
AT rosenmarci understandingopportunitiesandchallengeswithtelemedicinedeliveredbuprenorphineduringthecovid19pandemic